Muscle and Fat Mass Modulation in Different Clinical Models

  • Ruxandra Draghia-Akli
  • Amir S. Khan
Part of the Methods in Molecular Biology™ book series (MIMB, volume 423)

Abstract

Studies described in the recent literature support the idea that gene therapy can lead to genuine clinical benefits when mediated by plasmid delivery in conjunction with electroporation. Plasmid-mediated muscle-targeted gene transfer offers the potential of a cost-effective pharmaceutical-grade therapy delivered by simple intramuscular injection. This approach is particularly appropriate for modulating muscle and fat mass and their intrinsic properties, from treatment of conditions such as cachexia associated with chronic diseases, autoimmune diseases, e.g., myasthenia gravis, to stimulation or suppression of appetite, and further to in vivo manipulation of glucose metabolism and fat deposition in patients with diabetes, or to basic studies of muscle-specific transcription factors and their impact in development. Recent innovations, including in situ electroporation, enabling sustained systemic protein delivery within the therapeutic range, are reviewed. Translation of these advances to human clinical trials will enable muscle- and fat-targeted gene therapy to become a viable therapeutic alternative.

Keywords

electroporation plasmid muscle fat body composition gene therapy 

References

  1. 1.
    1. Tan, P.H., Chan, C.L., and George, A.J. (2006) Strategies to improve non-viral vectors—potential applications in clinical transplantation. Expert. Opin. Biol. Ther. 6, 619–630.CrossRefPubMedGoogle Scholar
  2. 2.
    2. Wolff, J.A., Ludtke, J.J., Acsadi, G., Williams, P., and Jani, A. (1992) Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1, 363–369.CrossRefPubMedGoogle Scholar
  3. 3.
    3. Wolff, J.A., Malone, R.W., Williams, P., et al. (1990) Direct gene transfer into mouse muscle in vivo. Science. 247, 1465–1468.CrossRefPubMedGoogle Scholar
  4. 4.
    4. Acsadi, G., Dickson, G., Love, D.R., et al. (1991) Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature. 352, 815–818.CrossRefPubMedGoogle Scholar
  5. 5.
    5. Andre, F. and Mir, L.M. (2004) DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther. 11, S33–S42.CrossRefPubMedGoogle Scholar
  6. 6.
    6. Ratanamart, J. and Shaw, J.A. (2006) Plasmid-mediated muscle-targeted gene therapy for circulating therapeutic protein replacement: a tale of the tortoise and the hare? Curr. Gene Ther. 6, 93–110.CrossRefPubMedGoogle Scholar
  7. 7.
    7. Prud'homme, G.J., Glinka, Y., Khan, A.S., and Draghia-Akli, R. (2006) Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr. Gene Ther. 6, 243–273.CrossRefPubMedGoogle Scholar
  8. 8.
    8. Xiang, L., Murai, A., Sugahara, K., Yasui, A., and Muramatsu, T. (2003) Effects of leptin gene expression in mice in vivo by electroporation and hydrodynamics-based gene delivery. Biochem. Biophys. Res. Commun. 307, 440–445.CrossRefPubMedGoogle Scholar
  9. 9.
    9. Xiang, L., Murai, A., and Muramatsu, T. (2005) Mutated-leptin gene transfer induces increases in body weight by electroporation and hydrodynamics-based gene delivery in mice. Int. J. Mol. Med. 16, 1015–1020.PubMedGoogle Scholar
  10. 10.
    10. Wang, X.D., Liu, J., Yang, J.C., Chen, W.Q., and Tang, J.G. (2003) Mice body weight gain is prevented after naked human leptin cDNA transfer into skeletal muscle by electroporation. J. Gene Med. 5, 966–976.CrossRefPubMedGoogle Scholar
  11. 11.
    11. Wang, X.D., Tang, J.G., Xie, X.L., et al. (2005) A comprehensive study of optimal conditions for naked plasmid DNA transfer into skeletal muscle by electroporation. J. Gene Med. 7, 1235–1245.CrossRefPubMedGoogle Scholar
  12. 12.
    12. Maxwell, M.A., Cleasby, M.E., Harding, A., Stark, A., Cooney, G.J., and Muscat, G.E. (2005) Nur77 regulates lipolysis in skeletal muscle cells. Evidence for cross-talk between the β-adrenergic and an orphan nuclear hormone receptor pathway. J. Biol. Chem. 280, 12573–12584.CrossRefPubMedGoogle Scholar
  13. 13.
    13. Cleasby, M.E., Davey, J.R., Reinten, T.A., et al. (2005) Acute bidirectional manipulation of muscle glucose uptake by in vivo electrotransfer of constructs targeting glucose transporter genes. Diabetes. 54, 2702–2711.CrossRefPubMedGoogle Scholar
  14. 14.
    14. Roorda, B.D., Hesselink, M.K., Schaart, G., et al. (2005) DGAT1 overexpression in muscle by in vivo DNA electroporation increases intramyocellular lipid content. J. Lipid Res. 46, 230–236.CrossRefPubMedGoogle Scholar
  15. 15.
    15. Fujii, N., Boppart, M.D., Dufresne, S.D., Crowley, P.F., Jozsi, A.C., et al. (2004) Overexpression or ablation of JNK in skeletal muscle has no effect on glycogen synthase activity. Am. J. Physiol. Cell Physiol. 287, C200–C208.CrossRefPubMedGoogle Scholar
  16. 16.
    16. Rubenstrunk, A., Mahfoudi, A., and Scherman, D. (2004) Delivery of electric pulses for DNA electrotransfer to mouse muscle does not induce the expression of stress related genes. Cell Biol. Toxicol. 20, 25–31.CrossRefPubMedGoogle Scholar
  17. 17.
    17. Morley, J.E., Thomas, D.R., and Wilson, M.M. (2006) Cachexia: pathophysiology and clinical relevance. Am. J. Clin. Nutr. 83, 735–743.PubMedGoogle Scholar
  18. 18.
    18. Argiles, J.M., Busquets, S., Felipe, A., and Lopez-Soriano, F.J. (2006) Muscle wasting in cancer and ageing: cachexia versus sarcopenia. Adv. Gerontol. 18, 39–54.PubMedGoogle Scholar
  19. 19.
    19. Wanke, C. (2004) Pathogenesis and consequences of HIV-associated wasting. J. Acquir. Immune. Defic. Syndr. 37 (Suppl. 5), S277–S279.PubMedGoogle Scholar
  20. 20.
    20. Springer, J., Filippatos, G., Akashi, Y.J., and Anker, S.D. (2006) Prognosis and therapy approaches of cardiac cachexia. Curr. Opin. Cardiol. 21, 229–233.CrossRefPubMedGoogle Scholar
  21. 21.
    21. Nelson, K.A. (2000) The cancer anorexia-cachexia syndrome. Semin. Oncol. 27, 64–68.PubMedGoogle Scholar
  22. 22.
    22. Draghia-Akli, R., Hahn, K.A., King, G.K., Cummings, K., and Carpenter, R.H. (2002) Effects of plasmid mediated growth hormone releasing hormone in severely debilitated dogs with cancer. Mol. Ther. 6, 830–836.CrossRefPubMedGoogle Scholar
  23. 23.
    23. Khan, A.S., Anscombe, I.W., Cummings, K.K., Pope, M.A., Smith, L.C., and Draghia-Akli, R. (2005) Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice. Cancer Gene Ther. 12, 54–60.CrossRefPubMedGoogle Scholar
  24. 24.
    24. Schakman, O., Gilson, H., de Coninck, V., et al. (2005) Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology. 146, 1789–1797.CrossRefPubMedGoogle Scholar
  25. 25.
    25. Khan, A.S., Anscombe, I.W., Cummings, K.K., Pope, M.A., Smith, L.C., and Draghia-Akli, R. (2003) Effects of plasmid-mediated growth hormone releasing hormone supplementation on LL-2 adenocarcinoma in mice. Mol. Ther. 8, 459–466.CrossRefPubMedGoogle Scholar
  26. 26.
    26. Tone, C.M., Cardoza, D.M., Carpenter, R.H., and Draghia-Akli, R. (2004) Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs. Cancer Gene Ther. 11, 389–396.CrossRefPubMedGoogle Scholar
  27. 27.
    27. Morrison, W. (2002) Clinical evaluation of cancer patients. In: Morrison, W. (ed.). Cancer in dogs and cats: medical and surgical management, 2nd edn. Teton New Media, West Lafayette, IN, pp. 59–67.Google Scholar
  28. 28.
    28. Coletti, D., Moresi, V., Adamo, S., Molinaro, M., and Sassoon, D. (2005) Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. Genesis. 43, 120–128.CrossRefPubMedGoogle Scholar
  29. 29.
    29. Figueras, M., Busquets, S., Carbo, N., Almendro, V., Argiles, J.M., and Lopez-Soriano, F.J. (2005) Cancer cachexia results in an increase in TNF-α receptor gene expression in both skeletal muscle and adipose tissue. Int. J. Oncol. 27, 855–860.PubMedGoogle Scholar
  30. 30.
    30. Losen, M., Stassen, M.H., Martinez-Martinez, P., et al. (2005) Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain. 128, 2327–2337.CrossRefPubMedGoogle Scholar
  31. 31.
    31. Chen, H.H., Maeda, T., Mullett, S.J., and Stewart, A.F. (2004) Transcription cofactor Vgl-2 is required for skeletal muscle differentiation. Genesis. 39, 273–279.CrossRefPubMedGoogle Scholar
  32. 32.
    32. Galli, L.M., Willert, K., Nusse, R., et al. (2004) A proliferative role for Wnt-3a in chick somites. Dev. Biol. 269, 489–504.CrossRefPubMedGoogle Scholar
  33. 33.
    33. Draghia-Akli, R., Ellis, K.M., Hill, L.A., Malone, P.B., and Fiorotto, M.L. (2003) High-efficiency growth hormone releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASEB J. 17, 526–528.PubMedGoogle Scholar
  34. 34.
    34. Khan, A.S., Fiorotto, M.L., Cummings, K.K., Pope, M.A., Brown, P.A., and Draghia-Akli, R. (2003) Maternal GHRH plasmid administration changes pituitary cell lineage and improves progeny growth of pigs. Am. J. Physiol. Endocrinol. Metab. 285, E224–E231.PubMedGoogle Scholar
  35. 35.
    35. Draghia-Akli, R. and Fiorotto, M.L. (2004) A new plasmid-mediated approach to supplement somatotropin production in pigs. J. Anim. Sci. 82, E264–E269.PubMedGoogle Scholar
  36. 36.
    36. Li, X., Eastman, E.M., Schwartz, R.J., and Draghia-Akli, R. (1999) Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17, 241–245.CrossRefPubMedGoogle Scholar
  37. 37.
    37. Brown, P.A., Davis, W.C., and Draghia-Akli, R. (2004) Immune enhancing effects of growth hormone releasing hormone delivered by plasmid injection and electroporation. Mol. Ther. 10, 644–651.CrossRefPubMedGoogle Scholar
  38. 38.
    38. Apple, J.K., Davis, J.C., Stephenson, J., Hankins, J.E., Davis, J.R., and Beaty, S.L. (1999) Influence of body condition score on carcass characteristics and subprimal yield from cull beef cows. J. Anim. Sci. 77, 2660–2669.PubMedGoogle Scholar
  39. 39.
    39. Komaragiri, M.V., Casper, D.P., and Erdman, R.A. (1998) Factors affecting body tissue mobilization in early lactation dairy cows. 2. Effect of dietary fat on mobilization of body fat and protein. J. Dairy Sci. 81, 169–175.CrossRefPubMedGoogle Scholar
  40. 40.
    40. Dechow, C.D., Rogers, G.W., and Clay, J.S. (2002) Heritability and correlations among body condition score loss, body condition score, production and reproductive performance. J. Dairy Sci. 85, 3062–3070.CrossRefPubMedGoogle Scholar
  41. 41.
    41. DeRouen, S.M., Franke, D.E., Morrison, D.G., et al. (1994) Prepartum body condition and weight influences on reproductive performance of first-calf beef cows. J. Anim. Sci. 72, 1119–1125.PubMedGoogle Scholar

Copyright information

© Humana Press 2008

Authors and Affiliations

  • Ruxandra Draghia-Akli
    • 1
  • Amir S. Khan
    • 1
  1. 1.VGX Pharmaceuticals, Immune Therapeutics DivisionThe WoodlandsTXUSA

Personalised recommendations